Enliven Therapeutics (ELVN) News Today $21.57 -0.23 (-1.06%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$21.57 0.00 (0.00%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.20 Consensus Target Price from BrokeragesJune 19 at 1:15 AM | americanbankingnews.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the transaction, the chief executive officer now directly owns 952,892 shares in the company, valued at $21,135,144.56. This represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.June 18 at 8:24 PM | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Now Covered by The Goldman Sachs GroupJune 18 at 2:09 AM | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst UpgradeJune 18 at 1:12 AM | americanbankingnews.comGoldman Sachs initiates Enliven Therapeutics stock with Buy ratingJune 17 at 10:11 PM | investing.comEnliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial DataJune 17 at 10:11 PM | msn.comRobert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) StockJune 17 at 3:25 AM | americanbankingnews.comEnliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesJune 16 at 4:18 PM | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst UpgradeEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst UpgradeJune 16 at 10:42 AM | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Rating of "Buy" from AnalystsShares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy rating. The average 1-year priceJune 16 at 9:39 AM | marketbeat.comRobert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceRobert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday.June 16 at 9:26 AM | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Coverage Initiated by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research note on Monday. They issued a "buy" rating and a $37.00 price objective for the company.June 16 at 8:37 AM | marketbeat.comEnliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded WarrantsJune 15, 2025 | nasdaq.comEnliven Therapeutics stock falls after pricing capital raise of $200M via securities offeringJune 13, 2025 | msn.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Should You Sell?Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Should You Sell?June 13, 2025 | marketbeat.comEnliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 13, 2025 | prnewswire.comEnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 13, 2025 | prnewswire.comEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 CongressJune 13, 2025 | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesJune 12, 2025 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.34, for a total transaction of $135,606.78. Following the completion of the sale, the chief operating officer now owns 303,309 shares of the company's stock, valued at $6,169,305.06. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.June 11, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 67.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,714 shares oJune 11, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.1% - Time to Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 7.1% Higher - Still a Buy?June 10, 2025 | marketbeat.comBank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Bank of America Corp DE decreased its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 29.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,187 shares of the company's stock after sJune 9, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4% on Insider SellingEnliven Therapeutics (NASDAQ:ELVN) Trading Down 4% Following Insider SellingJune 6, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 7,500 SharesJune 6, 2025 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 7,500 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 7,500 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $20.03, for a total transaction of $150,225.00. Following the sale, the insider now directly owns 977,688 shares of the company's stock, valued at $19,583,090.64. The trade was a 0.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.June 5, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 7,500 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 7,500 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $20.05, for a total transaction of $150,375.00. Following the transaction, the chief executive officer now directly owns 965,392 shares of the company's stock, valued at $19,356,109.60. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.June 5, 2025 | marketbeat.comMillennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Millennium Management LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 108.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 50,804 shares of the company's stock after buying an additional 26,44June 5, 2025 | marketbeat.comAmeriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Ameriprise Financial Inc. purchased a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 35,059 shares of the company's stock, valued at approximately $789,000June 3, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for ELVN FY2025 Earnings?Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at Lifesci Capital boosted their FY2025 earnings estimates for Enliven Therapeutics in a research report issued to clients and investors on Thursday, May 29th. Lifesci Capital analyst S. Slutsky now expects that the company will eaJune 2, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $16.18, for a total value of $52,585.00. Following the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $372,140. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.May 31, 2025 | marketbeat.comBrokers Set Expectations for ELVN Q2 EarningsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2025 EPS estimates for Enliven Therapeutics in a research report issued to clients and investors on Thursday, May 29th. Lifesci Capital analyst S. Slutsky expects that the company will earnMay 31, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.2% - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 6.2% Higher - Here's WhyMay 30, 2025 | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 30, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Buy" by AnalystsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been given an average rating of "Buy" by the five ratings firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation onMay 24, 2025 | marketbeat.comEnliven Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $81,550.00 in StockMay 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust CorpNorthern Trust Corp raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 331,500 shares of the company's stock afMay 22, 2025 | marketbeat.comSoleus Capital Management L.P. Has $1.70 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Soleus Capital Management L.P. trimmed its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 68.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,405 shares of the company'sMay 21, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for ELVN EarningsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Enliven Therapeutics in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will earnMay 20, 2025 | marketbeat.comPolar Capital Holdings Plc Acquires 1,739,668 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 267.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,389,668 shares of the company'sMay 17, 2025 | marketbeat.comJanus Henderson Group PLC Purchases 290,153 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Janus Henderson Group PLC grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 27.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,331,877 shares of the company's stock after acquiring an additional 290,153 shares during the periMay 17, 2025 | marketbeat.comEnliven price target lowered to $27 from $36 at JonesResearchMay 16, 2025 | msn.comPatient Square Capital LP Increases Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Patient Square Capital LP grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 147.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 224,038 shares of the company's stock after buying an additional 133,466 shares during the period. EnlMay 16, 2025 | marketbeat.comNicholas Investment Partners LP Sells 16,110 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Nicholas Investment Partners LP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 157,635 shares of the company's stock after selling 16,110 shares during the period. NiMay 16, 2025 | marketbeat.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 14, 2025 | prnewswire.comEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 CongressMay 14, 2025 | prnewswire.comAnish Patel Sells 6,667 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 10, 2025 | insidertrades.comEnliven Therapeutics (ELVN) to Release Quarterly Earnings on TuesdayEnliven Therapeutics (NASDAQ:ELVN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-enliven-therapeutics-inc-stock/)May 8, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 5,030 SharesMay 6, 2025 | insidertrades.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.660.56▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼214▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zai Lab News Today Akero Therapeutics News Today Vaxcyte News Today PTC Therapeutics News Today Cytokinetics News Today Rhythm Pharmaceuticals News Today Krystal Biotech News Today Merus News Today ACADIA Pharmaceuticals News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN Stock Free ELVN Stock Alerts